U.S. Stock Market Midday Update

YD Bio, up 14.54%, with increased trading volume and no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

Stocks with High Trading Volume in the Industry

AbbVie, up 2.99%. Based on recent key news:

1. On August 18, Hisun Pharmaceutical and AbbVie reached a cooperation agreement, granting AbbVie exclusive rights for global development, production, and commercialization, with a potential total deal value exceeding $700 million. This news boosted market confidence and drove AbbVie’s stock price up.

2. On August 18, AbbVie announced a third-quarter dividend of $0.38 per share, with the last trading day on July 13 and the payment date on August 20. The dividend news enhanced investors' confidence in the company's financial stability, further driving the stock price up.

3. On August 17, analyst reports indicated that AbbVie is expected to launch new blockbuster products, with the market anticipating significant future business growth potential, which boosted investor optimism and drove the stock price up. The pharmaceutical industry is performing strongly overall, with significant capital inflow.

Amgen, up 1.43%. Based on recent key news:

1. On August 17, AstraZeneca announced the launch of Tezspire in China, a drug developed in collaboration with Amgen, which may drive Amgen's stock price up. Zhitong Finance

2. On August 17, Barclays raised Amgen's target price to $380, maintaining a neutral rating, which boosted market confidence. Gelonghui

3. On August 17, analyst ratings showed Amgen with a hold rating, not included in the recommended buy list, which may limit further stock price increases. MarketBeat The pharmaceutical industry is restructuring, with intensified competition.

Gilead Sciences, up 3.05%. Based on recent key news:

1. On August 18, BMO Capital analyst Evan Seigerman reiterated a buy rating on Gilead Sciences, with a target price of $174. This move enhanced market confidence and drove the stock price up. Data source: BMO Capital.

2. On August 18, a FactSet survey showed that analysts raised the median EPS estimate for Gilead Sciences for 2026 to -$0.45, with a target price of $162. This upward adjustment reflects the market's optimistic expectations for the company's future profitability. Data source: FactSet.

3. On August 18, market analysis indicated that although Gilead Sciences received a moderate buy rating, top analysts believe that five other stocks offer better investment value. This view may influence some investors' decisions. Data source: MarketBeat. The healthcare industry faces macroeconomic challenges, with significant capital inflow.

Stocks with High Market Capitalization in the Industry Forte Pharmaceuticals rose 2.91%. Based on recent key news:

1. On August 18, BMO Capital analyst Evan Seigerman maintained a buy rating on Vertex Pharmaceuticals and set a target price of $600. The company's stock closed at $515.55 yesterday. The analyst consensus is a strong buy, with an average target price of $565.32, indicating an upside potential of 9.65% from current levels. This news boosted market confidence in Forte Pharmaceuticals, driving the stock price up.

2. On August 16, MarketBeat noted that Vertex Pharmaceuticals was not included in the list of five stocks recommended by top analysts. Although Vertex Pharmaceuticals currently has a moderate buy rating among analysts, top analysts believe that the other five stocks offer better investment value. This news may have had an indirect impact on market sentiment towards Forte Pharmaceuticals.

3. On August 18, the animal health industry faced macroeconomic tightening pressures, causing Zoetis's stock price to drop to a 52-week low. Despite the launch of the new product Simparica Trio, cautious consumer spending led to a downward revision of the full-year outlook. This industry dynamic may have affected the market performance of Forte Pharmaceuticals. Macroeconomic tightening impacts the animal health industry